In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Regression To The Meanest: How Markets Value Pharma Stocks

Financial markets – the people and institutions that lend companies money and estimate their worth – see pharma companies as revenue-generating, profit-sharing black boxes. Growth earns companies a break from this simplistic view, but sooner or later market valuations of pharmas seem to regress to a mean based on revenue multiples. That mean is getting meaner.

Business Strategies Financing Growth

Medical Devices Aren’t Luxury Goods, So Why Does Medtech Try To Sell Them That Way?

Clinical outcomes, quality and total cost of care are driving hospital purchasing decisions more than ever before. Providers can no longer justify spending on medical devices as clinical luxuries without links to outcomes. ZS recommends five fundamental factors that medtech needs to successfully communicate outcomes-based value.

Commercial Business Strategies Market Access

Podcast: Trump's 100 Day Test

Trump-watchers, check out our new podcast covering Trump's first months in office and the full GOP policy agenda. (Free with registration.)

BioPharmaceutical US Election 2016 Policy & Regulation
Advertisement


 

Recent Tweets from In Vivo


 

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Managing Pharma's Competing Challenges In The New Health Economy

The shifts roiling the health care industry are creating an entirely new commercial landscape. PwC says that the way pharma companies opt to address three pivotal challenges – patient engagement, analytics and value – will affect not only their future, but the future direction of patient care, provider decisions and payment mechanisms.

Business Strategies Pricing Strategies

Cardio-Neuro Innovator LivaNova Prepares For Challenges Ahead

LivaNova was formed from the merger of cardiovascular disease therapy company Sorin Group and neuromodulation innovator Cyberonics. The role and place in the industry of this new mega group might not be obvious to all, but incoming CEO Damien McDonald already has a vision of creating a disciplined company that leverages synergies and gets closer to the customer base.

Business Strategies Growth

Integra Thinks High Margin, Differentiated Portfolio Can Deliver A Transformative 2017

Integra LifeSciences surged to industry-leading 12% sales growth in 2016, and that's before it prepares to consolidate two of the biggest acquisitions in its history. What is the strategy behind the success of the specialty surgery, orthopedics and tissue tech company that is looking at another double-digit sales uplift in 2017?

Orthopedics Wound Healing & Tissue Repair

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Germany's New High-Risk Assessment Medtech Scheme Off To Slow Start

Germany's new testing and treatment methods (NUBs) scheme for assessing benefit in high-risk products for inpatient use recently processed its first batch of applications. But, as with its longer-established outpatient products counterpart, it does not seem to be an instant success, says German reimbursement expert Ben Modley.

Health Technology Assessment Medical Device

New Trends In R&D Partnering: Biopharma’s Bet On The US Veterans Administration

The US Veterans Administration is attracting more interest from drugmakers seeking to grow their foothold in the lucrative – but scientifically challenging – market for CNS disorders. The allure comes from VA’s strong analytics and data crunching capabilities as well as its investigatory and trial management expertise in high-profile areas like traumatic brain injury, post-traumatic stress and major depression.

Research and Development Strategies Innovation

Companion Diagnostics: The Expanding Reach Of Personalized Medicine

Personalized medicine is becoming the hallmark of care in oncology, but its use is also increasing in other therapeutic areas including inflammation, respiratory, infectious diseases and central nervous system disorders, as scientific understanding of these diseases advances. The expansion of companion diagnostics beyond oncology has impacts on dealmaking, clinical practice and the R&D pipeline.

Personalized Medicine Innovation

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Trump’s Next 1,000 Days: Advice For The Pharma C-suite

Although signs suggest the Trump Administration is moving back to the establishment center, biopharma’s knowledge elites remain in the populists’ crosshairs. It’s vital to change the narrative on medicines and markets. In this brief opinion piece In Vivo provides seven ways for the C-suite to do just that.

BioPharmaceutical Leadership

Execs On The Move, April 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Personalized Medicine: A Patient Primer On Best Practice

Personalized medicine is focused on meeting patients’ needs, but it also has the potential to transform the delivery and financing of health care. In Vivo probes the path toward meeting both goals in an in-depth interview with Eleanor Perfetto, SVP for strategic initiatives at the National Health Council, the DC-based patient advocacy organization whose members include groups representing 133 million patients nationwide.

Personalized Medicine Leadership

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Medtechs Must Act Fast On New EU Regulations Or Face Gridlock

Following the recent vote in the European Parliament, the EU has finally adopted the Medical Device and IVD Regulations that were proposed back in September 2012. The texts, vastly longer and more complex than the three directives they are replacing, will establish a tougher regulatory code for the next decade or more, but where are the likely pressure points for industry and how can manufacturers prepare?

Regulation Market Access

The Rozy View: Medtechs, Negotiate With India’s Regulators And Don't Give Up On Japan

Late to the regulatory game India's government authorities may be, but device companies need to be on their toes to not lose out on vast future market opportunities as the "Make in India" program takes shape. That is the view of international device regulatory and market access expert Ed Rozynski. And while India is on the up, is Japan losing its attractiveness?

Market Access Asia Pacific

To Get Pricing Right, Pharma Must Understand Payer Behavior, Trump Or No Trump

When it comes to drug pricing, one size certainly doesn’t fit all. Biopharma firms need to devise and design appropriate pricing and commercial strategies for payers, a group of customers that don’t all care about the same things and, in some cases, whose needs may be diametrically opposed.

Reimbursement Pricing Debate

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

In Vivo's Deals Of The Month, March 2017

Free article: In Vivo's editors pick March's most significant deals, including Spero's Series C and Allergan's deal with Editas.

Deals Market Intelligence

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical

Deals In Depth: February 2017

Seattle Genetics added to its antibody-drug conjugate pipeline in a $2 billion deal with Immunomedics; LabCorp could buy the CRO PPD for $8 billion. Representing the majority of the $3.9 billion in biopharma financing, Perrigo sold to RPI Finance Trust its royalty stream on Tysabri for $2.2 billion.

Deals BioPharmaceutical
UsernamePublicRestriction

Register